Overview

Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer

Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether setting test groups of cisplatin + irinotecan + Krestin therapy as first-line treatment and chemotherapy (radiotherapy or radiotherapy + chemotherapy also allowed) combined with Krestin as second-line treatment after exacerbation and comparing with historical control or community control is appropriate as the protocol and regimen for the phase III clinical trial on extensive-stage disease (ED) small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Toyama
Treatments:
Camptothecin
Cisplatin
Irinotecan
Krestin
polysaccharide-K